In vitro amiodarone protein binding and its interaction with warfarin.
The binding of amiodarone to human plasma protein and to bovine serum albumin was studied by three different methods, ultracentrifugation, equilibrium dialysis and fluorescence spectroscopy. The fraction of amiodarone bound to plasma protein amounted to 96.3%. The changes in the binding properties of 1-anilino-naphthalene-8-sulfonate for bovine serum albumin using warfarin and amiodarone as independent inhibitors were analyzed in terms of binding site specificity. The findings indicated that amiodarone and warfarin have two different binding sites on bovine serum albumin, so a noncompetitive inhibition mechanism was indicated. On the basis of our data we cannot exclude other mechanisms of interaction besides direct displacement of one drug by another; nevertheless, metabolite interference between amiodarone and coagulation cofactors may better explain the enhancement of warfarin's pharmacological action in association with amiodarone.
D000638:Amiodarone / Q000097:blood*; D001572:Benzofurans / Q000097:blood*; D001665:Binding Sites; D001667:Binding, Competitive; D001798:Blood Proteins / Q000378:metabolism*; D003956:Dialysis; D006801:Humans; D011485:Protein Binding; D012710:Serum Albumin, Bovine / Q000378:metabolism; D013050:Spectrometry, Fluorescence; D014461:Ultracentrifugation; D014859:Warfarin / Q000097:blood*
D001572:Benzofurans; D001798:Blood Proteins; D012710:Serum Albumin, Bovine; D014859:Warfarin; D000638:Amiodarone